<DOC>
	<DOCNO>NCT01054248</DOCNO>
	<brief_summary>This randomise , open label trial , compare standard dose dihydroartemisinin-piperaquine ( DP ) standard fix artesunate-mefloquine regimen ( MAS3 ) long regimen artemether-lumefantrine ( ALN+ ) treatment uncomplicated malaria pregnant woman . The sample size 335 woman arm would 1005 woman total . Pregnant patient 2nd 3rd trimester acute uncomplicated malaria meet eligibility criterion ask participate study . The primary objective determine efficacy DP MAS3 superior ALN+ treatment uncomplicated malaria pregnancy . The study also incorporate dense pharmacokinetic study mefloquine artesunate ( 15 woman MAS3 arm ) population pharmacokinetic study mefloquine , piperaquine lumefantrine .</brief_summary>
	<brief_title>Randomised Trial 3 Artemisinin Combination Therapy Malaria Pregnancy</brief_title>
	<detailed_description>The 3 treatment regimen 3 day DHA-piperaquine ( DP ) , 3 day artesunate-mefloquine ( MAS3 ) mefloquine give 8,8,8 mg/kg per day augment dose 4 day ( 5 tab BID ) artemether- lumefantrine ( ALN+ ) . This focus efficacy safety . Patients randomize equally one three treatment group . Within trial two nested pharmacokinetic study comprise dense data 15 woman mefloquine artesunate sparse data mefloquine , lumefantrine piperaquine . Pregnant woman follow delivery day 63 later delivery infant follow end first year life The follow baby monthly 1 year ( summarize table ) . Visits include body weight , length , head circumference , arm circumference , physical examination , motor milestone observation caregiver interview , developmental examination monthly haematocrit stool test . The mother free bring infant time clinic investigation appropriate present complaint symptom carry necessary provide care infant . Infants born mother positive peripheral smear delivery risk congenital malaria actively screen weekly 2 month . In last study one congenital malaria P.falciparum occur day 21 infant sick cure artesunate . Infants positive malaria would PCR spot verify malaria congenital .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Dihydroartemisinin</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<mesh_term>Artemisinine</mesh_term>
	<criteria>Age 1845 year Viable pregnancy gestation assess ultrasound scan Microscopically confirm uncomplicated malaria ( parasitaemia ≥ 5/500 WBC ) Plasmodium falciparum Mixed infection ( i.e . P.falciparum &amp; P.vivax/ovale/malariae ) Plasmodium vivax/ovale/malariae Willingness ability comply study protocol duration trial Written inform consent provide No sign labour Additional criterion patient detail pharmacokinetic study group ( N=24 MAS3 arm ) : HCT &gt; 25 % ( base field read i.e . capillary sample ) P.falciparum monoinfection Agree stay clinic 7 day Written consent participate detail PK subgroup Known hypersensitivity study drug P.falciparum asexual stage parasitaemia ≥ 4 % RBCs Clinical laboratory feature severe malaria base WHO criteriaAppendix 1 Gastrointestinal dysfunction could alter absorption motility History know liver diseases chronic disease ( exclude thalassemia &amp; G6PD deficiency ) Presence intercurrent illness condition judgement investigator would place patient undue risk interfere result study Splenectomy Hematocrit ( HCT ) &lt; 20 % ( base field read i.e . capillary sample ) [ *NB : Dense mefloquine pharmacokinetic exclusion HCT &lt; 25 % ] Taking contraindicate medication History narcotic alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>pregnancy , malaria , artemisinin , vivax , falciparum</keyword>
</DOC>